The Oregon Cancer Center (OCC), a matrix Clinical Cancer Center at Oregon Health Science University (OHSU) with 173 members, was awarded a CCSG (P30) two years ago. Since that time, the Center has been assigned 33,000 square feet of new space for its headquarters (11,000 square feet) and a new basic research building (22,000 square feet). Having focused on strengthening our clinical research infrastructure, we have successfully recruited senior leaders in clinical cancer research, two of whom are now principal investigators of multi- institutional study groups and serve on the Leadership Council of the Center. In the past two years of CCSG support, our investigators- institutional therapeutic clinical trials have increased fourfold, we are now ranked fourth in accruals to SWOG studies, and we have tripled CCG accruals. Our experimental Therapeutics program has focused directly on transplantation and cancer immunology, in part responding to criticisms in the prior review and input from the external advisory team. Now known is the Transplantation/Immunology Program, this group focuses on immunological tolerance in transplantation and cancer immunology. Because of the cohesiveness of this smaller, more focused group this program has the highest frequency of inter- and intra-programmatic publications in our Center. In cancer control, we have recruited seasoned investigators to the Center and have reached a critical mass in four focus areas driving support of this program's investigator-initiated research portfolio from $300,000 annually to more than $5 million annually in two years. In the past three years we have recruited 42 new members, and, in the next five years, we will recruit no fewer than 27 more in collaboration with 10 departments and institutes. The mission of our Center is to support research designed to identify molecular defects in neoplastic cells and to exploit such knowledge to develop more effective strategies for diagnosis, treatment, prevention, and control of malignant diseases. Translational research projects have increased in all five of the programs, and. in the past two years, some of our best scientific research projects have already moved into Phase I clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA069533-06S1
Application #
6606470
Study Section
Subcommittee G - Education (NCI)
Program Officer
Rosenfeld, Bobby
Project Start
1997-08-01
Project End
2005-05-31
Budget Start
2002-06-07
Budget End
2003-05-31
Support Year
6
Fiscal Year
2002
Total Cost
$91,736
Indirect Cost
Name
Oregon Health and Science University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009584210
City
Portland
State
OR
Country
United States
Zip Code
97239
Risom, Tyler; Langer, Ellen M; Chapman, Margaret P et al. (2018) Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer. Nat Commun 9:3815
Minnier, Jessica; Pennock, Nathan D; Guo, Qiuchen et al. (2018) RNA-Seq and Expression Arrays: Selection Guidelines for Genome-Wide Expression Profiling. Methods Mol Biol 1783:7-33
Su, Yulong; Pelz, Carl; Huang, Tao et al. (2018) Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals. Genes Dev 32:1398-1419
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Krey, Jocelyn F; Scheffer, Deborah I; Choi, Dongseok et al. (2018) Mass spectrometry quantitation of proteins from small pools of developing auditory and vestibular cells. Sci Data 5:180128
Rozanov, Dmitri V; Rozanov, Nikita D; Chiotti, Kami E et al. (2018) MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection. J Proteomics 176:13-23
Winters-Stone, Kerri M; Wood, Lisa J; Stoyles, Sydnee et al. (2018) The Effects of Resistance Exercise on Biomarkers of Breast Cancer Prognosis: A Pooled Analysis of Three Randomized Trials. Cancer Epidemiol Biomarkers Prev 27:146-153
Pennock, Nathan D; Martinson, Holly A; Guo, Qiuchen et al. (2018) Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer. J Immunother Cancer 6:98
Xu, Li; Gordon, Ryan; Farmer, Rebecca et al. (2018) Precision therapeutic targeting of human cancer cell motility. Nat Commun 9:2454
Chen, Emerson Y; Blanke, Charles D; Haller, Daniel G et al. (2018) A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. Am J Clin Oncol 41:1193-1198

Showing the most recent 10 out of 277 publications